We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals
LGND

357 hedge funds and large institutions have $4.15B invested in Ligand Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 133 increasing their positions, 115 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 43

22% more call options, than puts

Call options by funds: $8.48M | Put options by funds: $6.95M

16% more repeat investments, than reductions

Existing positions increased: 133 | Existing positions reduced: 115

7% more capital invested

Capital invested by funds: $3.89B → $4.15B (+$264M)

2% more funds holding

Funds holding: 349 → 357 (+8)

0% more funds holding in top 10

Funds holding in top 10: 8 → 8 (0)

0.18% less ownership

Funds ownership: 104.47% → 104.29% (-0.18%)

Holders
357
Holders Change
+8
Holders Change %
+2.29%
% of All Funds
4.39%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
59
Increased
133
Reduced
115
Closed
43
Calls
$8.48M
Puts
$6.95M
Net Calls
+$1.54M
Net Calls Change
-$3.42M

Top Buyers

1
Invesco
Invesco
Georgia
+$60.8M
2
NCGI
Next Century Growth Investors
Minnesota
+$19M
3
Bessemer Group
Bessemer Group
New Jersey
+$16.7M
4
Franklin Resources
Franklin Resources
California
+$15.2M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$12.9M

Top Sellers

1
UBS AM
UBS AM
Illinois
-$29.8M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$21M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$18.9M
4
NAMI
Nomura Asset Management International
Pennsylvania
-$14M
5
Goldman Sachs
Goldman Sachs
New York
-$9.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
SACTSONJ
376
Supplemental Annuity Collective Trust (SACT) of New Jersey
New Jersey
– -$244K -1,290 Closed
Rafferty Asset Management
377
Rafferty Asset Management
New York
– -$240K -1,270 Closed
Mackenzie Financial
378
Mackenzie Financial
Ontario, Canada
– -$227K -1,195 Closed
SFI
379
Susquehanna Fundamental Investments
Pennsylvania
– -$224K -1,184 Closed
DTL
380
Dynamic Technology Lab
Singapore
– -$214K -1,130 Closed
Allianz Asset Management
381
Allianz Asset Management
Germany
– -$204K -1,080 Closed
Acadian Asset Management
382
Acadian Asset Management
Massachusetts
– -$176K -933 Closed
SOW
383
State of Wyoming
Wyoming
– -$169K -894 Closed
PAP
384
Persistent Asset Partners
Hong Kong
– -$150K -791 Closed
TWM
385
Tripletail Wealth Management
Florida
– -$130K -710 Closed
BC
386
Bayforest Capital
United Kingdom
– -$72.8K -385 Closed
MPW
387
MASECO Private Wealth
– -$52K -275 Closed
KAS
388
Kestra Advisory Services
Texas
– -$31.4K -166 Closed
DB
389
Danske Bank
Denmark
– -$18.9K -100 Closed
Daiwa Securities Group
390
Daiwa Securities Group
Japan
– -$11K -58 Closed
AAP
391
Arax Advisory Partners
Colorado
– -$9.45K -50 Closed
GAFA
392
Garton & Associates Financial Advisors
Kentucky
– -$4.73K -25 Closed
ACM
393
Aster Capital Management
United Arab Emirates
– -$3.59K -19 Closed
GWM
394
Greenline Wealth Management
Florida
– -$3.08K -16 Closed
CIA
395
Cape Investment Advisory
Georgia
– -$1.51K -8 Closed
ACA
396
American Capital Advisory
Idaho
– -$757 -4 Closed
OC
397
Optima Capital
Oregon
– -$567 -3 Closed
DT
398
DV Trading
Illinois
– -$189 -1 Closed
FHA
399
Flagship Harbor Advisors
Massachusetts
– -$189 -1 Closed
TCM
400
TD Capital Management
Tennessee
– -$189 -1 Closed
12 13 14 15
16

LGND Hedge Fund Activity: Q1 2026 in Review

357 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2026, worth a combined $4.15B — up 6.8% from $3.89B a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new LGND positions and 43 closed out — a net gain of 16 holders — while 133 added to existing stakes and 115 trimmed.

The largest buyer was Invesco, adding an estimated $60.8M. The largest seller was UBS AM, cutting an estimated $29.8M.

  • 357 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2026, up from 349 in Q4 2025.
  • Funds reported $4.15B of Ligand Pharmaceuticals stock for Q1 2026, up 6.8% quarter-over-quarter.
  • 59 funds opened new Ligand Pharmaceuticals positions in Q1 2026 and 43 closed out, a net change of +16 holders.
  • The largest Ligand Pharmaceuticals buyer in Q1 2026 was Invesco, an estimated $60.8M added.
  • The largest Ligand Pharmaceuticals seller in Q1 2026 was UBS AM, an estimated $29.8M sold.

Based on aggregated 13F filings for Q1 2026.